Intrinsic value of Innoviva - INVA

Previous Close

$12.58

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$12.58

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of INVA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  148.15
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  134
  214
  331
  495
  719
  1,014
  1,394
  1,871
  2,457
  3,162
  3,994
  4,959
  6,063
  7,308
  8,695
  10,224
  11,893
  13,700
  15,641
  17,714
  19,916
  22,244
  24,695
  27,267
  29,959
  32,772
  35,704
  38,758
  41,936
  45,239
  48,673
Variable operating expenses, $m
 
  18
  27
  41
  59
  83
  114
  153
  201
  259
  327
  407
  497
  599
  713
  838
  975
  1,123
  1,283
  1,453
  1,633
  1,824
  2,025
  2,236
  2,457
  2,687
  2,928
  3,178
  3,439
  3,710
  3,991
Fixed operating expenses, $m
 
  18
  19
  19
  20
  20
  21
  21
  22
  22
  23
  24
  24
  25
  25
  26
  27
  27
  28
  29
  29
  30
  31
  32
  33
  33
  34
  35
  36
  37
  38
Total operating expenses, $m
  25
  36
  46
  60
  79
  103
  135
  174
  223
  281
  350
  431
  521
  624
  738
  864
  1,002
  1,150
  1,311
  1,482
  1,662
  1,854
  2,056
  2,268
  2,490
  2,720
  2,962
  3,213
  3,475
  3,747
  4,029
Operating income, $m
  109
  178
  285
  435
  640
  911
  1,259
  1,696
  2,234
  2,880
  3,643
  4,529
  5,542
  6,684
  7,957
  9,359
  10,891
  12,549
  14,330
  16,233
  18,254
  20,389
  22,639
  24,999
  27,470
  30,051
  32,742
  35,545
  38,461
  41,493
  44,644
EBITDA, $m
  123
  201
  320
  487
  715
  1,016
  1,404
  1,892
  2,490
  3,210
  4,060
  5,047
  6,175
  7,447
  8,864
  10,427
  12,133
  13,979
  15,963
  18,082
  20,333
  22,712
  25,217
  27,846
  30,598
  33,472
  36,470
  39,591
  42,839
  46,216
  49,726
Interest expense (income), $m
  49
  26
  11
  18
  27
  39
  56
  77
  103
  136
  175
  221
  274
  335
  404
  481
  566
  658
  758
  866
  981
  1,102
  1,231
  1,367
  1,510
  1,659
  1,814
  1,977
  2,146
  2,322
  2,505
Earnings before tax, $m
  60
  153
  274
  418
  613
  871
  1,203
  1,620
  2,131
  2,745
  3,469
  4,308
  5,268
  6,349
  7,552
  8,878
  10,325
  11,891
  13,572
  15,367
  17,273
  19,287
  21,407
  23,632
  25,960
  28,392
  30,928
  33,568
  36,315
  39,171
  42,139
Tax expense, $m
  0
  41
  74
  113
  166
  235
  325
  437
  575
  741
  937
  1,163
  1,422
  1,714
  2,039
  2,397
  2,788
  3,210
  3,665
  4,149
  4,664
  5,207
  5,780
  6,381
  7,009
  7,666
  8,350
  9,063
  9,805
  10,576
  11,378
Net income, $m
  60
  111
  200
  305
  448
  636
  878
  1,182
  1,555
  2,004
  2,532
  3,145
  3,845
  4,635
  5,513
  6,481
  7,537
  8,680
  9,908
  11,218
  12,609
  14,080
  15,627
  17,251
  18,951
  20,726
  22,577
  24,505
  26,510
  28,595
  30,762

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  150
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  379
  366
  566
  847
  1,229
  1,733
  2,383
  3,199
  4,200
  5,405
  6,827
  8,477
  10,364
  12,492
  14,863
  17,477
  20,330
  23,418
  26,737
  30,281
  34,045
  38,023
  42,213
  46,610
  51,212
  56,020
  61,033
  66,253
  71,685
  77,332
  83,202
Adjusted assets (=assets-cash), $m
  229
  366
  566
  847
  1,229
  1,733
  2,383
  3,199
  4,200
  5,405
  6,827
  8,477
  10,364
  12,492
  14,863
  17,477
  20,330
  23,418
  26,737
  30,281
  34,045
  38,023
  42,213
  46,610
  51,212
  56,020
  61,033
  66,253
  71,685
  77,332
  83,202
Revenue / Adjusted assets
  0.585
  0.585
  0.585
  0.584
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
  0.585
Average production assets, $m
  188
  300
  463
  693
  1,006
  1,419
  1,950
  2,618
  3,438
  4,423
  5,587
  6,938
  8,482
  10,224
  12,164
  14,303
  16,638
  19,166
  21,882
  24,782
  27,863
  31,119
  34,548
  38,146
  41,913
  45,847
  49,950
  54,223
  58,668
  63,290
  68,094
Working capital, $m
  178
  53
  81
  122
  177
  249
  343
  460
  604
  778
  982
  1,220
  1,492
  1,798
  2,139
  2,515
  2,926
  3,370
  3,848
  4,358
  4,899
  5,472
  6,075
  6,708
  7,370
  8,062
  8,783
  9,534
  10,316
  11,129
  11,974
Total debt, $m
  716
  314
  494
  746
  1,090
  1,544
  2,129
  2,863
  3,764
  4,848
  6,128
  7,613
  9,312
  11,227
  13,361
  15,713
  18,281
  21,060
  24,047
  27,237
  30,624
  34,205
  37,976
  41,933
  46,075
  50,402
  54,913
  59,612
  64,500
  69,583
  74,866
Total liabilities, $m
  732
  330
  510
  762
  1,106
  1,560
  2,145
  2,879
  3,780
  4,864
  6,144
  7,629
  9,328
  11,243
  13,377
  15,729
  18,297
  21,076
  24,063
  27,253
  30,640
  34,221
  37,992
  41,949
  46,091
  50,418
  54,929
  59,628
  64,516
  69,599
  74,882
Total equity, $m
  -353
  37
  57
  85
  123
  173
  238
  320
  420
  540
  683
  848
  1,036
  1,249
  1,486
  1,748
  2,033
  2,342
  2,674
  3,028
  3,404
  3,802
  4,221
  4,661
  5,121
  5,602
  6,103
  6,625
  7,168
  7,733
  8,320
Total liabilities and equity, $m
  379
  367
  567
  847
  1,229
  1,733
  2,383
  3,199
  4,200
  5,404
  6,827
  8,477
  10,364
  12,492
  14,863
  17,477
  20,330
  23,418
  26,737
  30,281
  34,044
  38,023
  42,213
  46,610
  51,212
  56,020
  61,032
  66,253
  71,684
  77,332
  83,202
Debt-to-equity ratio
  -2.028
  8.560
  8.720
  8.810
  8.870
  8.910
  8.930
  8.950
  8.960
  8.970
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
  9.000
Adjusted equity ratio
  -2.162
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  60
  111
  200
  305
  448
  636
  878
  1,182
  1,555
  2,004
  2,532
  3,145
  3,845
  4,635
  5,513
  6,481
  7,537
  8,680
  9,908
  11,218
  12,609
  14,080
  15,627
  17,251
  18,951
  20,726
  22,577
  24,505
  26,510
  28,595
  30,762
Depreciation, amort., depletion, $m
  14
  22
  35
  52
  75
  106
  146
  195
  257
  330
  417
  518
  633
  763
  908
  1,067
  1,242
  1,430
  1,633
  1,849
  2,079
  2,322
  2,578
  2,847
  3,128
  3,421
  3,728
  4,046
  4,378
  4,723
  5,082
Funds from operations, $m
  39
  134
  235
  357
  523
  742
  1,024
  1,378
  1,812
  2,334
  2,949
  3,663
  4,478
  5,398
  6,421
  7,549
  8,779
  10,110
  11,541
  13,068
  14,689
  16,402
  18,205
  20,098
  22,079
  24,148
  26,305
  28,551
  30,888
  33,318
  35,843
Change in working capital, $m
  -22
  20
  29
  40
  55
  73
  93
  117
  144
  173
  205
  238
  272
  306
  341
  376
  411
  444
  478
  510
  542
  573
  603
  633
  662
  692
  721
  751
  782
  813
  845
Cash from operations, $m
  61
  107
  206
  316
  468
  669
  931
  1,260
  1,668
  2,160
  2,744
  3,425
  4,207
  5,091
  6,080
  7,173
  8,368
  9,666
  11,063
  12,558
  14,147
  15,829
  17,603
  19,465
  21,417
  23,456
  25,583
  27,800
  30,106
  32,505
  34,999
Maintenance CAPEX, $m
  0
  -14
  -22
  -35
  -52
  -75
  -106
  -146
  -195
  -257
  -330
  -417
  -518
  -633
  -763
  -908
  -1,067
  -1,242
  -1,430
  -1,633
  -1,849
  -2,079
  -2,322
  -2,578
  -2,847
  -3,128
  -3,421
  -3,728
  -4,046
  -4,378
  -4,723
New CAPEX, $m
  0
  -112
  -163
  -230
  -313
  -413
  -532
  -668
  -820
  -986
  -1,164
  -1,351
  -1,544
  -1,742
  -1,941
  -2,139
  -2,335
  -2,528
  -2,716
  -2,900
  -3,080
  -3,256
  -3,429
  -3,599
  -3,767
  -3,934
  -4,103
  -4,273
  -4,445
  -4,622
  -4,804
Cash from investing activities, $m
  -5
  -126
  -185
  -265
  -365
  -488
  -638
  -814
  -1,015
  -1,243
  -1,494
  -1,768
  -2,062
  -2,375
  -2,704
  -3,047
  -3,402
  -3,770
  -4,146
  -4,533
  -4,929
  -5,335
  -5,751
  -6,177
  -6,614
  -7,062
  -7,524
  -8,001
  -8,491
  -9,000
  -9,527
Free cash flow, $m
  56
  -19
  20
  52
  103
  181
  293
  447
  653
  918
  1,251
  1,658
  2,145
  2,717
  3,376
  4,126
  4,966
  5,897
  6,917
  8,024
  9,217
  10,494
  11,852
  13,289
  14,803
  16,394
  18,059
  19,800
  21,615
  23,505
  25,471
Issuance/(repayment) of debt, $m
  -18
  -402
  180
  253
  344
  454
  585
  734
  901
  1,084
  1,280
  1,485
  1,698
  1,915
  2,134
  2,352
  2,568
  2,780
  2,987
  3,190
  3,387
  3,581
  3,770
  3,957
  4,142
  4,327
  4,512
  4,698
  4,888
  5,083
  5,283
Issuance/(repurchase) of shares, $m
  -79
  811
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -97
  409
  180
  253
  344
  454
  585
  734
  901
  1,084
  1,280
  1,485
  1,698
  1,915
  2,134
  2,352
  2,568
  2,780
  2,987
  3,190
  3,387
  3,581
  3,770
  3,957
  4,142
  4,327
  4,512
  4,698
  4,888
  5,083
  5,283
Total cash flow (excl. dividends), $m
  -40
  -421
  200
  305
  447
  635
  878
  1,181
  1,554
  2,002
  2,530
  3,143
  3,843
  4,632
  5,510
  6,478
  7,534
  8,676
  9,904
  11,214
  12,605
  14,075
  15,622
  17,246
  18,945
  20,720
  22,571
  24,498
  26,503
  28,588
  30,754
Retained Cash Flow (-), $m
  10
  -540
  -20
  -28
  -38
  -50
  -65
  -82
  -100
  -120
  -142
  -165
  -189
  -213
  -237
  -261
  -285
  -309
  -332
  -354
  -376
  -398
  -419
  -440
  -460
  -481
  -501
  -522
  -543
  -565
  -587
Prev. year cash balance distribution, $m
 
  150
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  0
  180
  276
  409
  585
  813
  1,100
  1,454
  1,882
  2,388
  2,978
  3,654
  4,419
  5,273
  6,217
  7,249
  8,367
  9,572
  10,859
  12,228
  13,677
  15,203
  16,806
  18,485
  20,240
  22,070
  23,976
  25,960
  28,023
  30,167
Discount rate, %
 
  15.40
  16.17
  16.98
  17.83
  18.72
  19.65
  20.64
  21.67
  22.75
  23.89
  25.08
  26.34
  27.66
  29.04
  30.49
  32.02
  33.62
  35.30
  37.06
  38.92
  40.86
  42.90
  45.05
  47.30
  49.67
  52.15
  54.76
  57.50
  60.37
  63.39
PV of cash for distribution, $m
 
  0
  133
  173
  212
  248
  277
  296
  303
  297
  280
  254
  221
  185
  149
  115
  85
  61
  41
  27
  17
  10
  6
  3
  2
  1
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products includes RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company is also entitled to a 15% interest related to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. Innoviva, Inc. has long-acting muscarinic antagonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

FINANCIAL RATIOS  of  Innoviva (INVA)

Valuation Ratios
P/E Ratio 22.7
Price to Sales 10.2
Price to Book -3.9
Price to Tangible Book
Price to Cash Flow 22.4
Price to Free Cash Flow 22.4
Growth Rates
Sales Growth Rate 148.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 19
Current Ratio 0
LT Debt to Equity -200.6%
Total Debt to Equity -202.8%
Interest Coverage 2
Management Effectiveness
Return On Assets 27.7%
Ret/ On Assets - 3 Yr. Avg. 0.9%
Return On Total Capital 15.9%
Ret/ On T. Cap. - 3 Yr. Avg. -6.4%
Return On Equity -17.2%
Return On Equity - 3 Yr. Avg. -150.9%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 91.8%
EBITDA Margin - 3 Yr. Avg. -177.3%
Operating Margin 81.3%
Oper. Margin - 3 Yr. Avg. -94.8%
Pre-Tax Margin 44.8%
Pre-Tax Margin - 3 Yr. Avg. -305.1%
Net Profit Margin 44.8%
Net Profit Margin - 3 Yr. Avg. -696.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 1.7%

INVA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the INVA stock intrinsic value calculation we used $134 million for the last fiscal year's total revenue generated by Innoviva. The default revenue input number comes from 2016 income statement of Innoviva. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our INVA stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.4%, whose default value for INVA is calculated based on our internal credit rating of Innoviva, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Innoviva.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of INVA stock the variable cost ratio is equal to 8.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $18 million in the base year in the intrinsic value calculation for INVA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.6% for Innoviva.

Corporate tax rate of 27% is the nominal tax rate for Innoviva. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the INVA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for INVA are equal to 139.9%.

Life of production assets of 13.4 years is the average useful life of capital assets used in Innoviva operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for INVA is equal to 24.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-353 million for Innoviva - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 105.485 million for Innoviva is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Innoviva at the current share price and the inputted number of shares is $1.3 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
GSK GlaxoSmithKlin 43.91 prem.  prem.
ARDM Aradigm 1.34 prem.  prem.
MRK Merck&Co 65.54 prem.  prem.
VRTX Vertex Pharmac 129.23 prem.  prem.
DVAX Dynavax Techno 10.00 prem.  prem.

COMPANY NEWS

▶ ETFs with exposure to Innoviva, Inc. : June 20, 2017   [Jun-20-17 03:02PM  Capital Cube]
▶ Can This Biotech Stock With 645% EPS Growth Launch New Breakout?   [Jun-02-17 11:40AM  Investor's Business Daily]
▶ Innoviva misses 1Q profit forecasts   [Apr-27-17 05:54PM  Associated Press]
▶ Sarissa Takes Innoviva to Court Over Busted Agreement   [Apr-22-17 10:00AM  TheStreet.com]
▶ Here's Why Innoviva Inc. Lost 10% Today   [06:08PM  Motley Fool]
▶ Innoviva Board Sends Letter to Shareholders   [08:30AM  Business Wire]
▶ Innoviva Board Sends Letter to Shareholders   [08:30AM  Business Wire]
▶ Sarissa Names 3 for Innoviva Board   [Mar-13-17 05:17PM  TheStreet.com]
▶ Innoviva Issues Press Statement   [12:12PM  Business Wire]
▶ Is EnPro Industries, Inc. (NPO) a Good Stock to Buy?   [Dec-12-16 01:10PM  at Insider Monkey]
▶ Hedge Funds Cant Get Enough of Innoviva Inc (INVA)   [Dec-07-16 09:48PM  at Insider Monkey]
▶ Glaxo and Innoviva Get Positive News (GSK, INVA)   [Dec-02-16 11:27AM  at Investopedia]
▶ GSK seeking FDA approval for 'triple combination' COPD therapy   [Nov-21-16 11:15AM  at bizjournals.com]
Stock chart of INVA Financial statements of INVA Annual reports of INVA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.